Sarah Louise Mackie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sarah Louise Mackie has a total of 149 co-authors. Here are the top co-authors by number of shared publications:
- Ann Wendy Morgan
School of Medicine, University of Leeds, Leeds, UK
7 shared publications - Christian David Mallen
Keele Staffordshire ST5 5BG School of Medicine and Centre for Musculoskeletal Health Research , Keele University
4 shared publications - Emma Harris
School of Health, Wellbeing and Social Care, Faculty of Wellbeing, Education and Language Studies, The Open University , Walton Hall, Kents Hill, Milton Keynes MK7 6AA
4 shared publications - Kornelis S. M. van der Geest
Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
4 shared publications Bhaskar Dasgupta
Southend University Hospitals NHS Trust , UK
3 shared publicationsColin T. Pease
3 shared publications
Latest Publications
- Open Access
- 15 December 2025
- Published by National Institute for Health and Care Research
- Vol. 5, 122
The polymyalgia paradox: Addressing north-south inequities in polymyalgia rheumatica using grassroots community connectors in a deprived urban area
Background Polymyalgia rheumatica (PMR) is a common cause of severe body pain in older people. PMR is treated with long-term glucocorticoids (“steroids”). Clinicians are concerned about the potential health impacts of PMR and its treatment. The charity PMRGCAuk (Polymyalgia Rheumatica and Giant Cell Arteritis UK) has fewer support groups in the North of England compared to the South. Aims of the Project We aimed to find out more about things that can make it difficult for people with PMR to get the diagnosis, care and support that they need. Methods A Northern Outreach Lead surveyed charity members. People with PMR made short videos about their experience https://pmrgca.org.uk/get-support/your-stories . These videos inspired further discussions between people living with PMR and professionals, held both in-person and online. We evaluated our project to help us reflect on what worked and what didn’t. Key Findings - What professionals say about PMR does not always make sense to patients. - Having PMR can contribute to social isolation and a sense of feeling alone. - Not all patients are getting the help and support they need. Patient and public involvement (PPI) Using local expertise, we sought to move from “consultative” PPI towards a partnership approach. Future plans We will build on this partnership to raise public awareness; to challenge PMR myths and misinformation; and to improve education and support for all clinicians who look after patients with PMR.
- 15 December 2025
- Published by National Institute for Health and Care Research
- Vol. 5, 122
Open AccessThe polymyalgia paradox: Addressing north-south inequities in polymyalgia rheumatica using grassroots community connectors in a deprived urban area
Background Polymyalgia rheumatica (PMR) is a common cause of severe body pain in older people. PMR is treated with long-term glucocorticoids (“steroids”). Clinicians are concerned about the potential health impacts of PMR and its treatment. The charity PMRGCAuk (Polymyalgia Rheumatica and Giant Cell Arteritis UK) has fewer support groups in the North of England compared to the South. Aims of the Project We aimed to find out more about things that can make it difficult for people with PMR to get the diagnosis, care and support that they need. Methods A Northern Outreach Lead surveyed charity members. People with PMR made short videos about their experience https://pmrgca.org.uk/get-support/your-stories . These videos inspired further discussions between people living with PMR and professionals, held both in-person and online. We evaluated our project to help us reflect on what worked and what didn’t. Key Findings - What professionals say about PMR does not always make sense to patients. - Having PMR can contribute to social isolation and a sense of feeling alone. - Not all patients are getting the help and support they need. Patient and public involvement (PPI) Using local expertise, we sought to move from “consultative” PPI towards a partnership approach. Future plans We will build on this partnership to raise public awareness; to challenge PMR myths and misinformation; and to improve education and support for all clinicians who look after patients with PMR.
- Open Access
- 19 June 2024
- Published by Springer Nature in Eye
- Vol. 38 (12) , 2437-2447
The spectrum of giant cell arteritis through a rheumatology lens
Treatment of giant cell arteritis (GCA) aims initially to prevent acute visual loss, and subsequently to optimise long-term quality of life. Initial prevention of acute visual loss in GCA is well-standardised with high-dose glucocorticoid therapy but in the longer term optimising quality of life requires tailoring of treatment to the individual. The licensing of the IL-6 receptor inhibitor tocilizumab combined with advances in vascular imaging have resulted in many changes to diagnostic and therapeutic practice. Firstly, GCA is a systemic disease that may involve multiple vascular territories and present in diverse ways. Broadening of the “spectrum” of what is called GCA has been crystallised in the 2022 GCA classification criteria. Secondly, the vascular inflammation of GCA frequently co-exists with the extracapsular musculoskeletal inflammation of the related disease, polymyalgia rheumatica (PMR). Thirdly, GCA care must often be delivered across multiple specialities and healthcare organisations requiring effective interprofessional communication. Fourthly, both GCA and PMR may follow a chronic or multiphasic disease course; long-term management must be tailored to the individual patient’s needs. In this article we focus on some areas of current rheumatology practice that ophthalmologists need to be aware of, including comprehensive assessment of extra-ocular symptoms, physical signs and laboratory markers; advanced imaging techniques; and implications for multi-speciality collaboration.
- 19 June 2024
- Published by Springer Nature in Eye
- Vol. 38 (12) , 2437-2447
Open AccessThe spectrum of giant cell arteritis through a rheumatology lens
Treatment of giant cell arteritis (GCA) aims initially to prevent acute visual loss, and subsequently to optimise long-term quality of life. Initial prevention of acute visual loss in GCA is well-standardised with high-dose glucocorticoid therapy but in the longer term optimising quality of life requires tailoring of treatment to the individual. The licensing of the IL-6 receptor inhibitor tocilizumab combined with advances in vascular imaging have resulted in many changes to diagnostic and therapeutic practice. Firstly, GCA is a systemic disease that may involve multiple vascular territories and present in diverse ways. Broadening of the “spectrum” of what is called GCA has been crystallised in the 2022 GCA classification criteria. Secondly, the vascular inflammation of GCA frequently co-exists with the extracapsular musculoskeletal inflammation of the related disease, polymyalgia rheumatica (PMR). Thirdly, GCA care must often be delivered across multiple specialities and healthcare organisations requiring effective interprofessional communication. Fourthly, both GCA and PMR may follow a chronic or multiphasic disease course; long-term management must be tailored to the individual patient’s needs. In this article we focus on some areas of current rheumatology practice that ophthalmologists need to be aware of, including comprehensive assessment of extra-ocular symptoms, physical signs and laboratory markers; advanced imaging techniques; and implications for multi-speciality collaboration.
- Open Access
- 25 May 2024
- Published by Elsevier in Journal of Autoimmunity
- Vol. 147, 103260
Polymyalgia rheumatica shows metabolomic alterations that are further altered by glucocorticoid treatment: Identification of metabolic correlates of fatigue
- 25 May 2024
- Published by Elsevier in Journal of Autoimmunity
- Vol. 147, 103260
Open AccessPolymyalgia rheumatica shows metabolomic alterations that are further altered by glucocorticoid treatment: Identification of metabolic correlates of fatigue
- 2 November 2023
- Published by Elsevier in The Lancet Rheumatology
- Vol. 5 (12) , e703-e705
Tocilizumab and glucocorticoids for giant cell arteritis: the learning curve
- 2 November 2023
- Published by Elsevier in The Lancet Rheumatology
- Vol. 5 (12) , e703-e705
Tocilizumab and glucocorticoids for giant cell arteritis: the learning curve
- Open Access
- 24 October 2023
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 8 (1) , rkad082
Jaw claudication and jaw stiffness in giant cell arteritis: secondary analysis of a qualitative research dataset
Objective: Jaw symptoms can be a vital clue to the diagnosis of GCA. Guidelines recommend more intensive treatment if jaw claudication is present. We sought to explore how patients with GCA described their jaw symptoms. Methods: We carried out a secondary, qualitative analysis of interview data from 36 participants from the UK (n = 25) and Australia (n = 11), originally collected in order to develop a patient-reported outcome measure for GCA. In all cases, GCA had been confirmed by biopsy/imaging. Interview transcripts were organized within QSR NVivo 12 software and analysed using template analysis. Themes were refined through discussion among the research team, including a patient partner. Results: Twenty of 36 participants reported jaw symptoms associated with GCA. The median age of these 20 participants was 76.5 years; 60% were female. Five themes were identified: physical sensations; impact on function; impact on diet; symptom response with CSs; and attribution to other causes. Physical sensations included ache, cramp, stiffness and ‘lockjaw’. Functional impacts included difficulty in eating/chewing, cleaning teeth, speaking or opening the mouth. Dietary impacts included switching to softer food. Response to CSs was not always immediate. Jaw symptoms were initially mis-attributed by some participants to arthritis, age or viral illnesses; or by health-care professionals to a dental cavity, ear infection or teeth-grinding. Conclusion: Jaw symptoms in GCA are diverse and can lead to diagnostic confusion with primary temporomandibular joint disorder, potentially contributing to delay in GCA diagnosis. Further research is needed to determine the relationship of jaw stiffness to jaw claudication.
- 24 October 2023
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 8 (1) , rkad082
Open AccessJaw claudication and jaw stiffness in giant cell arteritis: secondary analysis of a qualitative research dataset
Objective: Jaw symptoms can be a vital clue to the diagnosis of GCA. Guidelines recommend more intensive treatment if jaw claudication is present. We sought to explore how patients with GCA described their jaw symptoms. Methods: We carried out a secondary, qualitative analysis of interview data from 36 participants from the UK (n = 25) and Australia (n = 11), originally collected in order to develop a patient-reported outcome measure for GCA. In all cases, GCA had been confirmed by biopsy/imaging. Interview transcripts were organized within QSR NVivo 12 software and analysed using template analysis. Themes were refined through discussion among the research team, including a patient partner. Results: Twenty of 36 participants reported jaw symptoms associated with GCA. The median age of these 20 participants was 76.5 years; 60% were female. Five themes were identified: physical sensations; impact on function; impact on diet; symptom response with CSs; and attribution to other causes. Physical sensations included ache, cramp, stiffness and ‘lockjaw’. Functional impacts included difficulty in eating/chewing, cleaning teeth, speaking or opening the mouth. Dietary impacts included switching to softer food. Response to CSs was not always immediate. Jaw symptoms were initially mis-attributed by some participants to arthritis, age or viral illnesses; or by health-care professionals to a dental cavity, ear infection or teeth-grinding. Conclusion: Jaw symptoms in GCA are diverse and can lead to diagnostic confusion with primary temporomandibular joint disorder, potentially contributing to delay in GCA diagnosis. Further research is needed to determine the relationship of jaw stiffness to jaw claudication.
- 6 July 2023
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 62, 152239
Test-retest reliability of pain VAS/NRS, stiffness VAS/NRS, HAQ-DI and mHAQ in polymyalgia rheumatica: An OMERACT study
- 6 July 2023
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 62, 152239
Test-retest reliability of pain VAS/NRS, stiffness VAS/NRS, HAQ-DI and mHAQ in polymyalgia rheumatica: An OMERACT study
- 22 May 2023
- Published by Elsevier in The Lancet Rheumatology
- Vol. 5 (6) , e307-e308
Game-changing therapies for people with giant cell arteritis?
- 22 May 2023
- Published by Elsevier in The Lancet Rheumatology
- Vol. 5 (6) , e307-e308
Game-changing therapies for people with giant cell arteritis?
- Open Access
Common comorbidities in polymyalgia rheumatica and giant cell arteritis: cross-sectional study in UK Biobank
Objective To determine prevalent comorbidities in cases with polymyalgia rheumatica (PMR) or giant cell arteritis (GCA) compared to matched controls. Methods Nested, cross sectional case-control study within UK Biobank. Case status was defined as self-reported prior diagnosis of PMR or GCA. 10 controls per case were matched for age, sex, ethnicity and assessment centre. Associations with selected self-reported comorbidities were studied using conditional logistic regression. Results Of PMR (n=1036) or GCA (n=102) cases, 72% were female, 98% white and 58% reported current use of glucocorticoids. Mean age was 63. At the time of the assessment visit, compared to controls, PMR/GCA cases were more likely to report poor general health and at least several days of low mood in the two past weeks. PMR was associated with hypothyroidism (odds ratio (OR) 1.34, 95% confidence interval (CI) 1.07-1.67) and ever-use of hormone replacement therapy (OR 1.26, CI 1.07-1.47). Regarding common comorbidities, PMR and GCA were both associated with hypertension (PMR: OR 1.21, CI 1.06-1.39; GCA: OR 1.86, CI 1.23-2.81) and cataract (PMR: OR 1.51, CI 1.19-1.93; GCA: OR 3.84, CI 2.23-6.60). Additionally GCA was associated with depression (OR 3.05, CI 1.59-5.85). Neither were associated with diabetes. Conclusion Participants with a history of PMR/GCA, including those not currently taking glucocorticoids, rated their health as poorer than matched controls,. Some previously-described disease associations (hypothyroidism and early menopause) were replicated. Hypertension and cataract, which can both be exacerbated by long-term glucocorticoid therapy, were over-represented in both diseases, particularly GCA. Key messages Comorbidity was common in individuals with self-reported prior diagnosis of PMR/GCA. PMR/GCA were associated with poorer self-reported health than controls; GCA was associated with depression. Hypertension and cataract were over-represented in PMR/GCA compared with controls but diabetes was not.
Open AccessCommon comorbidities in polymyalgia rheumatica and giant cell arteritis: cross-sectional study in UK Biobank
Objective To determine prevalent comorbidities in cases with polymyalgia rheumatica (PMR) or giant cell arteritis (GCA) compared to matched controls. Methods Nested, cross sectional case-control study within UK Biobank. Case status was defined as self-reported prior diagnosis of PMR or GCA. 10 controls per case were matched for age, sex, ethnicity and assessment centre. Associations with selected self-reported comorbidities were studied using conditional logistic regression. Results Of PMR (n=1036) or GCA (n=102) cases, 72% were female, 98% white and 58% reported current use of glucocorticoids. Mean age was 63. At the time of the assessment visit, compared to controls, PMR/GCA cases were more likely to report poor general health and at least several days of low mood in the two past weeks. PMR was associated with hypothyroidism (odds ratio (OR) 1.34, 95% confidence interval (CI) 1.07-1.67) and ever-use of hormone replacement therapy (OR 1.26, CI 1.07-1.47). Regarding common comorbidities, PMR and GCA were both associated with hypertension (PMR: OR 1.21, CI 1.06-1.39; GCA: OR 1.86, CI 1.23-2.81) and cataract (PMR: OR 1.51, CI 1.19-1.93; GCA: OR 3.84, CI 2.23-6.60). Additionally GCA was associated with depression (OR 3.05, CI 1.59-5.85). Neither were associated with diabetes. Conclusion Participants with a history of PMR/GCA, including those not currently taking glucocorticoids, rated their health as poorer than matched controls,. Some previously-described disease associations (hypothyroidism and early menopause) were replicated. Hypertension and cataract, which can both be exacerbated by long-term glucocorticoid therapy, were over-represented in both diseases, particularly GCA. Key messages Comorbidity was common in individuals with self-reported prior diagnosis of PMR/GCA. PMR/GCA were associated with poorer self-reported health than controls; GCA was associated with depression. Hypertension and cataract were over-represented in PMR/GCA compared with controls but diabetes was not.
- Open Access
- 3 May 2023
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 62 (11) , 3710-3714
Does the halo count on temporal and axillary ultrasound predict time to relapse in giant cell arteritis?
To determine whether the halo count (HC) on temporal and axillary artery US (TAUS) predicts time to relapse in giant cell arteritis (GCA). We conducted a single-centre retrospective study of GCA patients. HC, the number of vessels with non-compressible halo on the TAUS at diagnosis, was determined by retrospective review of the US report and images. Relapse was defined as increase in GCA disease activity requiring treatment escalation. Cox proportional hazard regression was used to identify predictors of time to relapse. A total of 72 patients with confirmed GCA were followed up for a median of 20.9 months. Thirty-seven of 72 (51.4%) relapsed during follow-up, at a median prednisolone dose of 9 mg (range 0–40 mg). Large-vessel (axillary artery) involvement did not predict relapse. On univariable analysis, a higher HC was associated with shorter time to relapse (per-halo hazard ratio 1.15, 95% CI 1.02, 1.30; P = 0.028). However, statistical significance was lost when the 10 GCA patients with an HC of zero were excluded from analysis. In this real-world setting, relapse occurred at a wide range of glucocorticoid doses and was not predicted by axillary artery involvement. GCA patients with a higher HC at diagnosis were significantly more likely to relapse, but significance was lost on excluding those with HC of zero. HC is feasible in routine care and may be worth incorporating into future prognostic scores. Further research is required to determine whether confirmed GCA patients with negative TAUS represent a qualitatively different subphenotype within the GCA disease spectrum.
- 3 May 2023
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 62 (11) , 3710-3714
Open AccessDoes the halo count on temporal and axillary ultrasound predict time to relapse in giant cell arteritis?
To determine whether the halo count (HC) on temporal and axillary artery US (TAUS) predicts time to relapse in giant cell arteritis (GCA). We conducted a single-centre retrospective study of GCA patients. HC, the number of vessels with non-compressible halo on the TAUS at diagnosis, was determined by retrospective review of the US report and images. Relapse was defined as increase in GCA disease activity requiring treatment escalation. Cox proportional hazard regression was used to identify predictors of time to relapse. A total of 72 patients with confirmed GCA were followed up for a median of 20.9 months. Thirty-seven of 72 (51.4%) relapsed during follow-up, at a median prednisolone dose of 9 mg (range 0–40 mg). Large-vessel (axillary artery) involvement did not predict relapse. On univariable analysis, a higher HC was associated with shorter time to relapse (per-halo hazard ratio 1.15, 95% CI 1.02, 1.30; P = 0.028). However, statistical significance was lost when the 10 GCA patients with an HC of zero were excluded from analysis. In this real-world setting, relapse occurred at a wide range of glucocorticoid doses and was not predicted by axillary artery involvement. GCA patients with a higher HC at diagnosis were significantly more likely to relapse, but significance was lost on excluding those with HC of zero. HC is feasible in routine care and may be worth incorporating into future prognostic scores. Further research is required to determine whether confirmed GCA patients with negative TAUS represent a qualitatively different subphenotype within the GCA disease spectrum.
- Open Access
- 9 February 2023
- Published by MDPI AG in Biomolecules
- Vol. 13 (2) , 343
An Automated Method for Artifical Intelligence Assisted Diagnosis of Active Aortitis Using Radiomic Analysis of FDG PET-CT Images
The aim of this study was to develop and validate an automated pipeline that could assist the diagnosis of active aortitis using radiomic imaging biomarkers derived from [18F]-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography (FDG PET-CT) images. The aorta was automatically segmented by convolutional neural network (CNN) on FDG PET-CT of aortitis and control patients. The FDG PET-CT dataset was split into training (43 aortitis:21 control), test (12 aortitis:5 control) and validation (24 aortitis:14 control) cohorts. Radiomic features (RF), including SUV metrics, were extracted from the segmented data and harmonized. Three radiomic fingerprints were constructed: A—RFs with high diagnostic utility removing highly correlated RFs; B used principal component analysis (PCA); C—Random Forest intrinsic feature selection. The diagnostic utility was evaluated with accuracy and area under the receiver operating characteristic curve (AUC). Several RFs and Fingerprints had high AUC values (AUC > 0.8), confirmed by balanced accuracy, across training, test and external validation datasets. Good diagnostic performance achieved across several multi-centre datasets suggests that a radiomic pipeline can be generalizable. These findings could be used to build an automated clinical decision tool to facilitate objective and standardized assessment regardless of observer experience.
- 9 February 2023
- Published by MDPI AG in Biomolecules
- Vol. 13 (2) , 343
Open AccessAn Automated Method for Artifical Intelligence Assisted Diagnosis of Active Aortitis Using Radiomic Analysis of FDG PET-CT Images
The aim of this study was to develop and validate an automated pipeline that could assist the diagnosis of active aortitis using radiomic imaging biomarkers derived from [18F]-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography (FDG PET-CT) images. The aorta was automatically segmented by convolutional neural network (CNN) on FDG PET-CT of aortitis and control patients. The FDG PET-CT dataset was split into training (43 aortitis:21 control), test (12 aortitis:5 control) and validation (24 aortitis:14 control) cohorts. Radiomic features (RF), including SUV metrics, were extracted from the segmented data and harmonized. Three radiomic fingerprints were constructed: A—RFs with high diagnostic utility removing highly correlated RFs; B used principal component analysis (PCA); C—Random Forest intrinsic feature selection. The diagnostic utility was evaluated with accuracy and area under the receiver operating characteristic curve (AUC). Several RFs and Fingerprints had high AUC values (AUC > 0.8), confirmed by balanced accuracy, across training, test and external validation datasets. Good diagnostic performance achieved across several multi-centre datasets suggests that a radiomic pipeline can be generalizable. These findings could be used to build an automated clinical decision tool to facilitate objective and standardized assessment regardless of observer experience.